Proteasome Inhibitors

• 

  Subject Areas on Research

  • Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. 
  • Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. 
  • Design and synthesis of naphthoquinone derivatives as antiproliferative agents and 20S proteasome inhibitors. 
  • Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. 
  • HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. 
  • Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity. 
  • Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. 
  • New betulinic acid derivatives as potent proteasome inhibitors. 
  • Novel therapies for pancreatic adenocarcinoma. 
  • Oncogenic RAS-induced CK1α drives nuclear FOXO proteolysis. 
  • Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. 
  • Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. 
  • Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. 
  • Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma. 
  • Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. 
  • Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients. 
  • Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. 
  • Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. 
  • Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation. 
  • Proteasome regulators: activators and inhibitors. 
  • Regulation of RIPK3- and RHIM-dependent Necroptosis by the Proteasome. 
  • Requirement of dendritic Akt degradation by the ubiquitin-proteasome system for neuronal polarity. 
  • Reversible mislocalization of a disease-associated MRE11 splice variant product. 
  • SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. 
  • Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. 
  • Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives. 
  • Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives. 
  • Synthesis and proteasome inhibition of lithocholic acid derivatives. 
  • The cyclophilin-like domain of Ran-binding protein-2 modulates selectively the activity of the ubiquitin-proteasome system and protein biogenesis. 
  • The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. 
  • Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. 
  • Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. 
  • Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.